Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Camurus AB (publ)
Camurus makes long-acting injectable medicines that treat opioid dependence, pain, cancer, and hormone-related conditions, and sells them to healthcare providers.
Camurus is a Swedish drugmaker that specializes in one tricky problem: getting powerful medicines to release slowly inside the body over weeks or months instead of all at once. Its core technology, called FluidCrystal, turns a drug into a tiny gel-like depot when it's injected under the skin. That depot then leaks the medicine out steadily, so patients get a long, even dose from a single shot rather than remembering to take a pill every day.
The company's flagship product is Buvidal, a once-monthly (and sometimes weekly) injection for opioid dependence. Instead of taking a daily dose of buprenorphine under the tongue, a patient gets one shot and is covered for weeks. That's a big deal for people whose lives are chaotic, and for the clinics trying to keep them in treatment. Camurus also sells medicines for severe pain, certain cancers, and endocrine disorders like acromegaly, using the same slow-release approach. The business earns money by selling these finished medicines to healthcare providers, and it also partners with larger drug companies who license its technology and pay it royalties on sales. Its main market is Europe, but Buvidal has been expanding into more countries, and the company has been building out its US presence. Competition comes from older daily treatments and from rival long-acting injectables, so the pitch is convenience and steadiness: one shot that works quietly in the background.
Camurus is a profitable, growing specialty pharma business rather than a sprawling giant. That means its fortunes ride heavily on a handful of products, especially Buvidal, so anything that dents that drug — a rival, a pricing squeeze, or a reimbursement problem — matters a lot. But the same focused bet is why it works: it found a clever delivery trick and turned it into medicines people actually struggle to take the old-fashioned way.
Saved answer · last researched 12 Nov 2026